Femoxetine

Femoxetine
Systematic (IUPAC) name
(3R,4S)-3-[(4-methoxyphenoxy)methyl]-1-methyl-4-phenyl-piperidine
Clinical data
Routes of
administration
Oral
Legal status
  • Uncontrolled
Pharmacokinetic data
Biological half-life 7-27 hours
Identifiers
CAS Number 59859-58-4
ATC code none
PubChem CID 3012003
ChemSpider 2280941 YesY
UNII 8Y719ZLX8C YesY
ChEMBL CHEMBL94739 YesY
Chemical data
Formula C20H25NO2
Molar mass 311.42 g/mol
  (verify)

Femoxetine (INN) (tentative brand name Malexil; developmental code name FG-4963) is a drug related to paroxetine that was being developed as an antidepressant by Danish pharmaceutical company Ferrosan in 1975 before acquisition by Novo Nordisk. It acts as a selective serotonin reuptake inhibitor (SSRI). Development was halted to focus attention on paroxetine instead, given femoxetine's inability to be administered as a daily pill.

Both femoxetine and paroxetine were invented in the 1970s by Jorgen Buus-Lassen (Jørgen Anders Christensen name on the patents though).[1][2] After Ferrosan's acquisition, femoxetine died from neglect.[3]

See also

References



This article is issued from Wikipedia - version of the Saturday, April 02, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.